ARTL
Artelo Biosciences, Inc. NASDAQ$3.30
Mkt Cap $7.0M
52w Low $2.96
0.4% of range
52w High $85.80
50d MA $5.02
200d MA $11.51
P/E (TTM)
-0.6x
EV/EBITDA
-0.2x
P/B
—
Debt/Equity
-0.5x
ROE
1012.5%
P/FCF
-0.3x
RSI (14)
—
ATR (14)
—
Beta
0.41
50d MA
$5.02
200d MA
$11.51
Avg Volume
3.5M
About
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal fo…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -4.71 | -6.66 | -41.4% | 3.90 | +2.3% | -6.9% | -4.6% | -8.5% | -12.3% | -15.4% | — |
| Nov 12, 2025 | AMC | -0.82 | -3.97 | -384.1% | 1.80 | +0.0% | +0.0% | +2.8% | +1.1% | +5.0% | +2.8% | — |
| Aug 13, 2025 | AMC | -4.19 | -5.61 | -33.9% | 10.13 | -3.4% | -0.4% | -1.1% | -3.7% | -2.3% | -5.4% | — |
| May 13, 2025 | AMC | -0.80 | -4.32 | -440.1% | 6.18 | +0.0% | -3.4% | -8.7% | -10.7% | -12.1% | -6.1% | — |
| Mar 3, 2025 | AMC | -2.62 | -7.02 | -167.9% | 6.00 | +0.0% | +3.0% | +2.0% | +0.0% | +0.0% | -1.0% | — |
| Nov 12, 2024 | AMC | -4.75 | -2.10 | +55.8% | 7.02 | -3.4% | -6.0% | -7.7% | -11.1% | +4.3% | -5.1% | — |
| Aug 13, 2024 | AMC | -4.76 | -4.50 | +5.5% | 7.80 | -0.8% | +1.5% | +3.1% | +0.0% | +0.0% | +0.8% | — |
| May 13, 2024 | AMC | -5.88 | -4.68 | +20.4% | 7.80 | +3.1% | +2.3% | +1.5% | +4.6% | +9.2% | +18.5% | — |
| Mar 25, 2024 | AMC | -3.34 | -5.94 | -77.8% | 9.06 | -6.6% | -4.6% | -2.6% | -2.0% | +0.7% | -0.7% | — |
| Nov 13, 2023 | AMC | -3.88 | -4.98 | -28.4% | 7.62 | -2.4% | +3.1% | +1.6% | -3.7% | -7.1% | -0.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 19 | Maxim Group | Downgrade | Buy → Hold | — | $1.89 | $1.87 | -1.1% | -2.1% | -9.5% | -11.6% | -5.8% | -8.5% |
| Sep 8 | D. Boral Capital | Downgrade | Buy → Hold | — | $4.51 | $4.50 | -0.2% | +0.9% | +3.8% | +7.1% | +9.1% | +17.7% |
| Aug 26 | D. Boral Capital | Maintains | Buy → Buy | — | $9.46 | $9.17 | -3.1% | -4.5% | -4.9% | -4.4% | -2.2% | -4.3% |
| Aug 18 | D. Boral Capital | Maintains | Buy → Buy | — | $10.02 | $10.00 | -0.2% | -2.6% | -1.2% | -4.4% | -4.9% | -6.7% |
| Aug 6 | D. Boral Capital | Maintains | Buy → Buy | — | $9.48 | $9.33 | -1.6% | -5.1% | -4.7% | -11.9% | +5.8% | +2.5% |
| Aug 4 | D. Boral Capital | Maintains | Buy → Buy | — | $10.20 | $9.64 | -5.5% | -2.6% | -7.1% | -11.8% | -11.5% | -18.1% |
| Jul 8 | D. Boral Capital | Upgrade | Hold → Buy | — | $14.32 | $16.38 | +14.4% | +11.0% | +50.8% | +99.0% | +66.8% | +29.5% |
| Jun 11 | D. Boral Capital | Downgrade | Buy → Hold | — | $6.78 | $6.60 | -2.7% | +6.2% | +4.4% | +6.2% | -5.6% | -7.8% |
| Jun 6 | D. Boral Capital | Maintains | Buy → Buy | — | $6.60 | $6.54 | -0.9% | +1.8% | +0.0% | +2.7% | +9.1% | +7.3% |
| Apr 28 | D. Boral Capital | Maintains | Buy → Buy | — | $6.24 | $6.24 | +0.0% | -2.9% | -2.9% | -5.8% | -2.9% | -1.9% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
ARTL faces potential Nasdaq delisting if it fails to meet compliance requirements at an upcoming hearing, creating significant downside risk to shareholders through loss of exchange listing and reduced liquidity.
Apr 7
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
ARTL is raising capital through a private placement, diluting existing shareholders but securing cash for operations without disclosing the amount or investor terms yet.
Mar 30
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
ARTL signed a material agreement with a laboratory partner, likely expanding testing capabilities or revenue streams, which investors should monitor for details on financial impact and strategic importance.
Mar 26
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
ARTL secured capital funding through Vanquish Funding Group, potentially strengthening cash position and operational flexibility, which investors should monitor for how it impacts dilution and debt terms.
Mar 18
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Artelo's delayed financial statements suggest potential compliance or operational issues that could trigger regulatory scrutiny, making the stock riskier for investors until clarity emerges on the filing status.
Mar 17
8-K · 8.01
!! High
Artelo Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Artelo Biosciences announced a reverse stock split effective March 6, 2026, a common delisting prevention measure that consolidates shares to increase per-share price and maintain exchange listing compliance.
Mar 6
8-K · 1.01
!! High
Artelo Biosciences, Inc. -- 8-K 1.01: Material Agreement
Artelo Biosciences secured $25 million in equity financing from Square Gate Capital Master Fund, strengthening its cash position for clinical development and operations.
Feb 5
8-K · 8.01
!! High
Artelo Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Artelo Biosciences faces potential Nasdaq delisting after failing to meet stockholder equity requirements; a hearing before the Panel provides temporary protection from suspension or delisting.
Feb 5
Data updated apr 24, 2026 7:03pm
· Source: massive.com